Rare diseases
Investigational molecules
Locations
989 East Hillsdale Boulevard Suite 220, 94404-3294, United States
Apollomics Inc. focuses on advanced malignancies with an emphasis on solid tumors that show MET dysregulation, including cancers marked by MET amplification, MET fusion, and MET overexpression.
The sponsor’s research activity centers on tumor types where MET pathway abnormalities are clinically relevant.
Apollomics Inc. runs clinical trials in conditions such as Neoplasm, Central nervous system neoplasm, Non-small cell lung cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
